Navigation Links
Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Date:5/17/2012

diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio. 

Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
Location: S405
Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.  Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
2. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
3. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
4. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
5. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
6. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
7. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
9. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
10. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
11. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 Amgen ... today announced results from several exploratory analyses of the ... low bone mineral density (BMD). Romosozumab is an investigational ... the protein sclerostin, thereby increasing bone formation and decreasing ... Society for Bone and Mineral Research (ASBMR) 2014 Annual ...
(Date:9/15/2014)... 2014 myMatrixx has extended its contract with ... an expanded role that includes direct involvement in the ... nationally recognized physiatrist and pain management specialist, published author, ... workers, compensation, is Board Certified in physical medicine and ... Pain Medicine and subspecialty boarded by the American Board ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
(Date:9/15/2014)... 15, 2014 The Best Hospitals ... Report consists of seven hospitals using OnBase as their ... and Cleveland Clinic were ranked at the top of ... The rankings cover nearly 5,000 medical centers across the ... hospitals that scored highest in at least six of ...
(Date:9/15/2014)... Randy Dotinga HealthDay Reporter ... Patients prescribed cholesterol-lowering drugs are more likely to fill ... are cheaper generic brands, new research suggests. At ... brands include Crestor, Zocor and Lipitor. Generic statins are ... risk of heart problems due to clogged arteries. ...
(Date:9/15/2014)... Worth, FL (PRWEB) September 15, 2014 ... policy away from putting low-level offenders in jail and ... Treatment Group sees this shift as a positive change. ... of prescription drug and heroin abuse. According to an ... both parties are calling for a shift away from ...
(Date:9/15/2014)... By Dennis Thompson ... (HealthDay News) -- The severe respiratory virus believed to ... Western states has now spread to the Northeast, health ... Health confirmed on Friday more than a dozen cases ... especially for children with asthma. And on Saturday, ...
(Date:9/15/2014)... 15, 2014 Array Health ... technology, today announced that Independence Blue Cross ... southeastern Pennsylvania, has selected the Array Spectrum™ Private ... exchange marketplace for employers with more than 100 ... Spectrum™, Independence will offer employer groups a comprehensive ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 3Health News:White House Shifts Policy on Drugs 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3
... East Hills, NY (Sept. 19, 2007) -- Each year ... critical part of their donation literally go down the ... collected annually, a majority (about two-thirds) of the four ... banks are replacing this valuable resource with much more ...
... Former Speaker of the,House and founder of the ... of conservative Republican lawmakers on Capitol Hill,today that while ... over the State Children,s Health Insurance Program (SCHIP) is ... insistent that Congress,not lose sight of the hundreds of ...
... Inc.,(OTC: ABOS) today announced Walter C. Ogier has resigned as ... of Directors. The Arbios Board,of Directors has appointed Shawn P. ... and CEO. The Company plans to,initiate a search for a ... Board of Directors has elected Amy,Factor as Vice Chairman. Ms. ...
... The majority of parents feel they play a ... according to researchers at the University of Michigan C.S. ... in the October issue of the Journal of Pediatrics, ... decisions made about their hospitalized childs medical care. Researchers ...
... million Americans who are living with cancer or have ... keeping their spirits intact: communication. In recognition of this, ... report by November 1, co-authored by a University of ... to good cancer care and deserves more research. , ...
... factor found at higher levels in these tumors, scientists say ... called nerve growth factor (NGF) may prove an effective target ... NGF is an essential component in the growth and differentiation ... in the Oct. 7 issue of the World Journal ...
Cached Medicine News:Health News:Critical blood shortages eased by new technology 2Health News:Critical blood shortages eased by new technology 3Health News:Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a 'Clean' SCHIP Six-Month Extension 2Health News:Arbios Announces Management Changes 2Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Communication in cancer world is key to survival 2
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: